Evaluating three biomarkers as prognostic factors of in-hospital mortality and severity in heart failure: A prospective cohort

Segura-Saldaña, Pedro; Chambergo‐Michilot, Diego; Alarcón‐Santos, Javier E.; Aguilar, Cristian; Álvarez-Vargas, Mayita Lizbeth; Padilla-Reyes, Marcos; León-Vivar, Rodrigo; Pariona, Marcos

doi:10.1016/j.repc.2021.03.010

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was noted that IL-6 had the highest specificity (75.35%) and sensitivity (100%). [ 38 ] Moreover, over a 1-year follow-up period, an optimal cut-off NLR level of 5.1 ng/ml was found to reliably estimate death in HF patients (sensitivity of 75% and specificity of 62%). [ 103 ] Although the NLR can be easily and readily obtained from a complete blood count without requiring another blood sample to be taken, IL-6 has a higher sensitivity and specificity; thus, supporting the rationale of using IL-6 as a superior prognostic biomarker.…”

Section: Discussionmentioning

confidence: 99%

“…It was noted that IL-6 had the highest specificity (75.35%) and sensitivity (100%). [ 38 ] To determine their prognostic role in cardiovascular events, a study measured plasma pentraxin 3 (PTX3) levels in people with HFpEF. A greater risk of cardiovascular events was linked to higher PTX3 levels (>3.0 ng/ml).…”

Section: Biomarkers To Assess Heart Failure Severitymentioning

confidence: 99%

See 1 more Smart Citation

Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review

Alzaabi,

Abdelsalam,

Alhammadi

et al. 2024

Card Fail Rev

View full text Add to dashboard Cite

There is a high prevalence of heart failure (HF) worldwide, which has significant consequences for healthcare costs, patient death and quality of life. Therefore, there has been much focus on finding and using biomarkers for early diagnosis, prognostication and therapy of HF. This overview of the research presents a thorough examination of the current state of HF biomarkers and their many uses. Their function in diagnosing HF, gauging its severity and monitoring its response to therapy are all discussed. Particularly promising in HF diagnosis and risk stratification are the cardiac-specific biomarkers, B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Markers of oxidative stress, extracellular matrix, renal function, inflammation and cardiac peptides have shown promise in evaluating HF severity and prognosis. MicroRNAs and insulin-like growth factor are two emerging biomarkers that have shown potential in helping with HF diagnosis and prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Biomarkers To Assess Heart Failure Severitymentioning

confidence: 99%